Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association

Chia-Chin Wu; Y. Alan Wang; J. Andrew Livingston; Jianhua Zhang; P. Andrew Futreal

doi:10.1038/s41467-021-27651-4

Nature Communications (Jan 2022)

Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association

Chia-Chin Wu,
Y. Alan Wang,
J. Andrew Livingston,
Jianhua Zhang,
P. Andrew Futreal

Affiliations

Chia-Chin Wu: Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
Y. Alan Wang: Department of Cancer Biology, The University of Texas MD Anderson Cancer Center
J. Andrew Livingston: Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center
Jianhua Zhang: Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
P. Andrew Futreal: Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center

DOI: https://doi.org/10.1038/s41467-021-27651-4
Journal volume & issue: Vol. 13, no. 1
pp. 1 – 14

Abstract

Read online

A lot of cancer patients are not responsive to anti-PD1 therapy. Here, the authors develop a network approach to identify genes, pathways and potential therapeutic combinations and develop an MHC-I gene immunoscore associated with tumour response to anti-PD1.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal